HS-V Softgel Capsule contains a combination of Clindamycin 100 mg and Clotrimazole 200 mg, formulated to provide effective treatment against mixed bacterial and fungal infections. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby exerting a bacteriostatic effect against susceptible aerobic and anaerobic Gram-positive and some Gram-negative bacteria. Clotrimazole is an imidazole antifungal agent that disrupts the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased membrane permeability and cell death. The synergistic action of these two agents makes HS-V Softgel Capsule particularly useful in managing infections where both bacterial and fungal pathogens are implicated, such as certain skin, soft tissue, and mucosal infections. This combination is indicated for the treatment of mixed infections including bacterial vaginosis with concurrent fungal involvement, dermatophytosis with secondary bacterial infection, and other similar conditions. The softgel formulation enhances bioavailability and patient compliance. HS-V Softgel Capsule should be used under medical supervision, with dosage and duration tailored according to the severity and type of infection. Caution is advised in patients with hypersensitivity to clindamycin, clotrimazole, or related compounds, and monitoring for potential adverse effects such as gastrointestinal disturbances and allergic reactions is recommended.